<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395003</url>
  </required_header>
  <id_info>
    <org_study_id>1503015459</org_study_id>
    <secondary_id>2R01HD028016-20A1</secondary_id>
    <secondary_id>2R01HD028016</secondary_id>
    <nct_id>NCT02395003</nct_id>
  </id_info>
  <brief_title>Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents</brief_title>
  <official_title>Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin Resistance is the best predictor of whether the obese adolescent will develop type 2&#xD;
      diabetes. The present studies will focus on determining what might cause fat to accumulate in&#xD;
      the subcutaneous fat regions and lead to local inflammation, causing insulin resistance to&#xD;
      develop in obese adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test whether the reduced transcription of key&#xD;
      lipogenic/adipogenic genes in abdominal subcutaneous adipose tissue (SAT) in obese&#xD;
      adolescents with a High VAT/SAT (visceral adipose tissue/subcutaneous adipose tissue) ratio&#xD;
      translates functionally into a reduced in vivo triglyceride (TG) synthesis and adipocyte&#xD;
      proliferation, which in turn will contribute to ectopic fat accumulation and insulin&#xD;
      resistance (IR). To test whether the storage capacity of gluteal SAT is linked to the level&#xD;
      of VAT/SAT fat distribution in obese adolescents. To explore if changes in dietary fat intake&#xD;
      (palmitate intake) alters ceramide concentration in both plasma and adipose tissue (AT) and&#xD;
      the Inflammasome complex in the different fat distribution phenotypes and their associations&#xD;
      with IR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>Fat Biopsies</measure>
    <time_frame>Baseline</time_frame>
    <description>1) To test whether the reduced transcription of key lipogenic/adipogenic genes in abd SAT in obese adolescents with a High VAT/SAT ratio translates functionally into a reduced in vivo TG synthesis and adipocyte proliferation, which in turn will contribute to ectopic fat accumulation and IR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Visceral to Subcutaneous fat storage ratio</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Pediatric Obesity</condition>
  <arm_group>
    <arm_group_label>High VAT/SAT high Palmitate Diet</arm_group_label>
    <description>Subjects with a high ratio of visceral to subcutaneous fat consuming high Palmatite oil diet for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low VAT/SAT</arm_group_label>
    <description>Subjects with a low ratio of visceral to subcutaneous fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean Controls</arm_group_label>
    <description>Lean control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High VAT/SAT- low Palmitate Diet</arm_group_label>
    <description>Subjects with a high ratio of visceral to subcutaneous fat consuming low Palmatite oil diet for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Palmitate Diet</intervention_name>
    <description>Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.</description>
    <arm_group_label>High VAT/SAT high Palmitate Diet</arm_group_label>
    <arm_group_label>Low VAT/SAT</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Basal plasma samples for measurements of glucose and glycerol enrichment, and glucose,&#xD;
      insulin FFAs, leptin, C-peptide, glucagon, adiponectin, cortisol, growth hormone,&#xD;
      catecholamines and amino acids, will be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obese adolescents&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overweight (85-95th% age and gender specific) or Obese (&gt;95th% age and gender&#xD;
             specific)&#xD;
&#xD;
          -  Ages 12-18 years&#xD;
&#xD;
          -  Absence of any endocrinopathy&#xD;
&#xD;
          -  Absence of any therapy with medication known to alter glucose metabolism (i.e.: Oral&#xD;
             steroids, certain psychiatric medications such as Xeleca, Lithium, Paxil)&#xD;
&#xD;
          -  English Speaking subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease known to alter glucose metabolism (T2DM)&#xD;
&#xD;
          -  Diuretic Medication&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Type 1 or 2 diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Caprio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica M Nouws, BS</last_name>
    <phone>203.785.6972</phone>
    <email>jessica.nouws@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bridget Pierpont, MA</last_name>
    <phone>203.785.2942</phone>
    <email>bridget.pierpont@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Pierpont</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

